Use of intravenous dofetilide in atrial flutter with hemodynamic instability

Acidosis inhibits spontaneous activity and membrane currents in myocytes isolated from the rabbit atrioventricular node

Recent evidence from intact hearts suggests that the function of cardiac nodal tissue may be particularly susceptible to acidosis. Little is currently known, however, about the effects of acidosis on the cellular electrophysiology of the atrioventricular node (AVN). This study was conducted, therefore, to determine the effect of acidosis on the spontaneous activity and membrane currents of myocytes isolated from the rabbit AVN, recorded at 35-37 degrees C using whole-cell patch-clamp. Reduction of extracellular pH (pH(e); from 7.4 to 6.8 or 6.3) produced pH-dependent slowing of spontaneous action potential rate and upstroke velocity, and reductions in maximum diastolic potential and action potential amplitude. Ionic current recordings under voltage-clamp indicated that acidosis (pH(e) 6.3) decreased L-type Ca current (I(Ca,L)), without significant changes in voltage-dependent activation or inactivation. Acidosis reduced the E-4031-sensitive, rapid delayed rectifier current (I(Kr)) tail amplitude at -40 mV following command pulses to between -30 and +50 mV, and accelerated tail-current deactivation. In contrast, the time-dependent hyperpolarisation-activated current, I(f), was unaffected by acidosis. Background current insensitive to E-4031 and nifedipine was reduced by acidosis. Measurement of intracellular pH (pH(i)) from undialysed cells using BCECF showed a reduction in mean pH(i) from 7.24 to 6.45 (n=17) when pH(e) was lowered from 7.4 to 6.3. We conclude that I(f) is unlikely to be involved in the response of the AVN to acidosis, whilst inhibition of I(Ca,L) and I(Kr) by acidosis are likely to play a significant role in effects on AVN cellular electrophysiology.

Dofetilide

Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X.

Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The May 2000 Formulary monographs are linezolid, pneumococcal 7-valent conjugate vaccine, apomorphine, levobetaxolol HCl, mequinol 2% and tretinoin 0.1% topical solution. The DUE is on dexmedetomidine.

Dofetilide versus quinidine for atrial flutter: viva la difference!?

Dofetilide is more effective than quinidine to terminate atrial flutter in this animal model. It is also more capable of lengthening refractoriness more uniformly than quinidine. While the investigators describe local changes in refractoriness and dispersion of refractoriness and wavelength meticulously, it is not clear which, if any, of these properties cause flutter termination or influence reinduction. This report provides new insight into the electrophysiologic mechanisms of antiarrhythmic drugs used to treat atrial arrhythmias. Related investigations are needed to expand our knowledge of the actions of antiarrhythmic drugs, how these drugs affect critical portions of the reentrant circuit, and how to identify potential adverse effects of these agents. Application of these data may help guide the use of antiarrhythmic drugs and allow development of safer, and yet more potent, compounds. At least, it will give us pause about using more toxic and less effective drugs. While Class III drugs, specifically dofetilide, may be more potent and beneficial than quinidine in this model, it is uncertain that these results pertain to human reentrant atrial arrhythmias, particularly, atrial flutter. Perhaps dofetilide will be effective for certain types of atrial flutter requiring an anatomical center defined by an area of injury or surgical scar in the right atrium. The fact that these, and previous, data indicate a specific beneficial effect of dofetilide, particularly on atrial flutter, is interesting. Even if dofetilide proves highly effective for human atrial flutter, its safety will need to be proven in large clinical trials. The most obvious concern about dofetilide is development of serious side effects such as torsades de pointes. Clinical trials of this drug for atrial arrhythmias are presently ongoing. Ultimately, the long-term use of such a drug is dependent on the emergence of other highly effective therapies such as radiofrequency ablation.